Poor Indoor Air Quality Linked to Cancer & Other Issues : Oncology Times
An abstract is unavailable.
Related Articles
Transforming Cancer Care Through Data: How Texas Colon & Rectal Specialists Enhances Outcomes, Experiences, and Efficiency
How Texas Colon & Rectal Specialists enhance outcomes, experiences, and efficiency data-driven care to improve patient outcome
Transient receptor potential melastatin 8 contributes to… : PAIN
critical contributor to neuropathic cold pain by interacting with the cold sensor transient receptor potential melastatin 8 (TRPM8). By using the St2−/− mice, we demonstrate…
Association of chronic pain with incidence and progression… : PAIN Reports
chronic pain and incidence of CMM and if it existed, to what extent chronic pain relates to the progression of specific CMD-related multimorbidity (MM). Methods:…
Blood-Based Test May Help Increase Colorectal Cancer Screening Rates
Additional local, regional, or national policy may bolster access to screening for colorectal cancer, according to Aasma Shaukat, MD, MPH.
Proteomic Assessment of the Risk of Secondary… : Journal of the American Society of Nephrology
ng of the circulating proteins associated with secondary cardiovascular events may help to identify novel therapeutic targets. Background Cardiovascular risk models have been developed primarily…
Intro to AYA Patients, Survivors, and Substance Use
Adolescent and young adult survivors of cancer face increased substance use risks due to developmental delays, limited support, and coping mechanisms, necessitating targeted prevention.
The 5th Annual OncoAlert Colloquium
The Year in Review in Oncology 2024 brought to you by some of the Worlds TOP experts!
GDF-15 Blockade Overcomes Resistance to Immune Checkpoint Inhibition
Main Findings: Visugromab, a GDF-15 blocking antibody, is tolerable and elicits clinical responses in combination with nivolumab.Concept: GDF-15 may represent a mechanism of anti-PD-1 resistance…
FDA Expands PATHWAY HER2 (4B5) Test to Include HER2-Ultralow Status
The PATHWAY HER2 (4B5) test is now FDA-approved to assess HER2-ultralow status in metastatic breast cancer, expanding its prior HER2-low indication.
CD22-Directed CAR-T Therapy Provides Durable Remission and Long-Term Survival in Large B-Cell Lymphoma
Among patients with large B-cell lymphoma progressing after CD19-directed CAR T-cell therapy, treatment with CD22-Directed CAR T-cells provided durable remissions and long-term survival after 3…
